THE DEAL, AT A GLANCE
From the announcementAcelyrin
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedAcelyrin raised $300M Series CFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersAcelyrin's $300M Series C positions the company as a top-decile Healthcare & Life Sciences financing event within a database segment that recorded 131 other trailing…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Acelyrin · Financing Record
Explore source-linked visual explanations for Acelyrin. Unsupported claims are withheld while source review continues.
Record 949 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →